Alexandria Hammond BofA Securities Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
14
Avg Return
Past Year
Past Year
16%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Buy
57.1%
Hold
28.6%
Sell
14.3%
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
89bio
ETNB
$2.2B
|
Buy
Maintained
| $29 |
96%
upside
| 1 | +57% |
0
%
| 25 Aug ‘25 1 month ago |
|
Akero Therapeutics
AKRO
$4.32B
|
Buy
Maintained
| $64 |
19%
upside
| 3 | +1% |
0
%
| 27 May ‘25 4 months ago |
|
Regeneron Pharmaceuticals
REGN
$59.8B
|
Buy
Initiated
| $1,150 |
104%
upside
| 1 | -28% |
0
%
| 15 Nov ‘24 11 months ago |
|
Pfizer
PFE
$141B
|
Sell
Initiated
| $25 |
1%
upside
| 1 | +4.8% |
0
%
| 15 Nov ‘24 11 months ago |
|
Moderna
MRNA
$10.4B
|
Sell
Initiated
| $40 |
49%
upside
| 1 | +33% |
0
%
| 15 Nov ‘24 11 months ago |
|
Merck
MRK
$215B
|
Hold
Initiated
| – | – | 1 | – |
–
| 15 Nov ‘24 11 months ago |
|
Eli Lilly
LLY
$747B
|
Buy
Initiated
| $1,000 |
20%
upside
| 1 | +6% |
0
%
| 15 Nov ‘24 11 months ago |
|
Johnson & Johnson
JNJ
$459B
|
Buy
Initiated
| $190 |
0%
downside
| 1 | +26% |
0
%
| 15 Nov ‘24 11 months ago |
|
Gilead Sciences
GILD
$145B
|
Buy
Initiated
| $110 |
6%
downside
| 1 | +27% |
0
%
| 15 Nov ‘24 11 months ago |
|
Bristol-Myers Squibb
BMY
$89.5B
|
Hold
Initiated
| – | – | 1 | – |
–
| 15 Nov ‘24 11 months ago |
|
Biogen
BIIB
$21.5B
|
Hold
Initiated
| – | – | 1 | – |
–
| 15 Nov ‘24 11 months ago |
|
AbbVie
ABBV
$407B
|
Buy
Initiated
| $205 |
11%
downside
| 1 | +36% |
0
%
| 15 Nov ‘24 11 months ago |
|